Celgene acquiring Juno for $9B

Celgene Corp. (NASDAQ:CELG) said it will acquire Juno Therapeutics Inc. (NASDAQ:JUNO) for $87 per share, or about $9 billion. The price is a 28% premium to Juno's close of $67.81 on Friday, before the deal was announced, and a 91% premium to its closing price of $45.60 on Jan. 16, when rumors circulated after market hours that a deal was in the works (see BioCentury Extra, Jan. 16).

Juno gained $18.19 (27%) to $86 on Monday. The companies expect the deal to close this quarter...